Prostat kanseri için yeni bir kemoterapik ilaç kombinasyonu

Prostate cancer as a multistep and complicated cancer type is regulated by androgens at the cellular level and remains as the second most common cause of death among men. The discovery of new chemotherapeutics through the development of novel agents which enable cell death rapidly without exerting serious toxic effects to healthy tissues might alter the depressing aspects of chemotherapy. In the current study, anti-cancer activity of a novel heterodinuclear copper(II)Mn(II) complex (Schiff base) and its P85 combination were evaluated by cell proliferation analysis, gene and protein expression assays, invasion experiments and antimicrobial analysis in vitro; reflecting the detailed molecular mechanisms, potential inhibitory role on metastasis and anti-inflammatory action. In order to assign maximum tolerated dose, toxicology analysis were performed on C57/B16 mice by determining blood counts, enzyme activities and histopathological examination of multiple organs. Tramp-C1 model was used to discover anti-tumor activity through the tumor volume measurements and Gleason score analysis in vivo. Overall, a remarkable anti-cancer activity was observed for Schiff base-P85 combination in vitro and in vivo for prostate cancer; however, a set of experiments are ongoing to elucidate exact mechanism at the molecular and physiological level. This study is the first one in the literature which represents the anti-cancer activity of a novel Schiff base derivative synthysized by our group and its P85 combination on prostate cancer.